Premaitha Health Test to be offered on the NHS

Premaitha Health Test to be offered on the NHS

National Screening Committee recommendation will enable more pregnant women to benefit from NIPT and sets reimbursement precedent for other regions.

Premaitha Health PLC, developer of the IONA® test, the first CE-marked non-invasive prenatal screening (NIPT) product, welcomes the UK National Screening Committee’s (NSC) recommendation to routinely offer NIPT testing on the NHS to high risk pregnant women as part of the standard fetal anomaly screening programme.

The recommendation states that the UK National Health Service (NHS) should offer NIPT to high risk pregnant women (those with a 1:150 chance of having a pregnancy affected by Down’s syndrome) to significantly reduce invasive testing such as amniocentesis, which carries a small miscarriage risk.

More than one in five pregnant women in the UK are now over 35. As expectant mothers get older there is an increasing chance that their pregnancies will be affected by Down’s syndrome with one in 40 pregnancies found to be high risk. This recommendation means that more British women will benefit from having access to NIPT. There are approximately 700,000 live births in the UK every year, this represents a significant and growing market for NIPT.

Dr Stephen Little, CEO of Premaitha Health said: “Today’s NSC recommendation is a key milestone for prenatal testing in the UK. This is the first time that NIPT will be routinely available to high risk pregnant women on the NHS and sets a precedent that we expect other countries to follow in the near future. This is an important step towards NIPT becoming available to all pregnant women, not just those at high risk. Premaitha is uniquely positioned to bring the benefits of NIPT to the NHS.

“Our CE-marked IONA® test has already been recognised as providing a superior NIPT product and support service. We partnered with St. George’s University Hospitals NHS Foundation Trust last year and together have created the UK’s first NIPT Centre of Excellence. As a British company at the heart of the Northern Powerhouse, we are extremely well placed to support the NHS with a rapid roll-out of NIPT across the UK. We look forward to enabling more pregnant women across the country to access NIPT through the NHS and to obtain safer, more accurate and faster results.”

Premaitha, directly and in partnership with St. George’s University Hospitals NHS Foundation Trust, has been providing NIPT to high-risk women on the NHS using Premaitha’s IONA® test (offered as the ‘SAFE test’ service through St George’s) since mid-2015. It also offers women at a lower risk the opportunity to take the test privately and enables other NHS and private clinics across the country to send maternal blood samples for screening. Premaitha anticipates that the endorsement by the NHS will accelerate private payer market growth in the UK.

Important information

This information is of a general nature and does not constitute an offer to provide services.

The opinions and conclusions given here are those of Seneca Partners and are subject to change without notice.

The value of investments and/or any income arising from them may fluctuate.

Past performance is not necessarily a guide to future performance.

Important notice

The products and services shown on this website place capital at risk. Investors may receive less in returns than they have invested. Investments may not allow for capital to be withdrawn on demand. If an investment provides tax relief then this relief is subject to change and is dependant on personal circumstances. Any reference to past performance or forecasted performance is not a reliable indicator of future performance.

Seneca Partners recommends that any investor seeks specialised financial and/or tax advice before investing. Seneca Partners does not provide advice and the information on this website, including but not limited to news, should not be construed as such.

Please confirm that you understand this warning and wish to proceed.